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ABSTRACT: 
Magnetic resonance imaging (MRI) is an excellent imaging modality. However the low 
sensitivity of the technique poses a challenge to achieving an accurate image of function at 
the molecular level. To overcome this, contrast agents are used; typically gadolinium based 
agents for T1 weighted imaging, or iron oxide based agents for T2 imaging. Traditionally, only 
one imaging mode is used per diagnosis although several physiological situations are known 
to interfere with the signal induced by the contrast agents in each individual imaging mode 
acquisition. Recently, the combination of both T1 and T2 imaging capabilities into a single 
platform has emerged as a tool to reduce uncertainties in MR image analysis. To date, 
contradicting reports on the effect on the contrast of the coupling of a T1 and T2 agent have 
hampered the application of these specialised probes. Herein, we present a systematic 
experimental study on a range of gadolinium-labelled magnetite nanoparticles envisioned to 
bring some light into the mechanism of interaction between T1 and T2 components, and 
advance towards the design of efficient (dual) T1 and T2 MRI probes. Unexpected behaviours 
observed in some of the constructs will be discussed. In this study, we demonstrate that the 
relaxivity of such multimodal probes can be rationally tuned to obtain unmatched potentials in 
MR imaging, exemplified by preparation of the magnetite-based nanoparticle with the highest 
T2 relaxivity described to date. 
 
INTRODUCTION: 
MRI is a powerful technique perfectly suited for biological imaging.1,2 Properties like non-
invasiveness, high penetration, high spatial resolution and absence of ionising radiations,2 
make it one of the first choices not only for human clinical diagnosis, but also for the monitoring 
of the progression of diseases/treatments, and for drug design. MRI images water protons, 
measuring the relaxation time of their nuclear magnetic spins once they have been excited 
with a radio-frequency pulse under a static magnetic field.3 The contrast in MR images arises 
from the different chemical environment of these water protons, which induces differences in 
the water proton relaxation times (T). This relaxation time can be greatly affected by the 
presence of paramagnetic or superparamagnetic compounds in the surroundings of the water 
molecules, leading to an enhanced contrast on the MR images. There are two major MRI 
modalities in use in hospitals when it comes to the use of contrast agents; T1- and T2-weighted 
imaging. Gadolinium-containing T1 contrast agents are the preferred contrast agent in the 
clinic as the enhanced signal produced is more favourable and easier to distinguish (although 
adipose tissue is a well-known interference).4 T2 agents such as iron oxide nanoparticles 
(IONPs), on the other hand produce a decrease in signal intensity which can be misinterpreted 
as bleeding, calcification or other abnomalies.5,6 Nanoparticles are a versatile platform to 
which targeting molecules and drugs can be coupled.7,8 Thus, having a single multifunctional 
probe integrating both T1 and T2 contrast capabilities can overcome the drawbacks of both 
MRI modalities, with compatible T1 and T2 acquisitions, allowing for artefacts to be reduced 
and diagnostics to be doubly verified. 
The earliest example of dual contrast T1/T2 MR imaging was carried out by Weissleder et al. 
to image liver tumours in rats. When Gd-DTPA and ferrite nanoparticles were co-administered, 
an enhanced tumour signal from the Gd-DTPA was observed while the liver showed a 
negative signal intensity from the accumulation of ferrite.9 Their results showed an increase in 
r1 but no effect on r2 when both agents were present at the same time. The same effect was 
observed when the contrast agents were administered sequentially in humans, in studies 
carried out by Semelka et al. and Kubaska et al.10,11 Theoretically, integration of the T1 and T2 
contrast as a single entity as opposed to having them separately, would result in T1 spins 
alignment in the same direction as the magnetic field induced by the T2 material, enhancing 
the T1 effect while maintaining the T2 signal.4,12 This theory was in part confirmed by 
experimental evidence from Gao et al.12 Gd2O3-embedded Fe3O4 nanoparticles (GdIO) were 
synthesised and presented a synergistic enhancement of r1 and r2. The GdIO showed higher 
r2 than Fe3O4 of similar size, as well as higher r1 than Gd2O3 of similar size. In addition to this, 
the Gd2O3 nanoparticles showed no enhanced T2 contrast, while Fe3O4 nanoparticles showed 
limited enhanced T1 contrast. Other inorganic hybrid systems combining T1 and T2 
nanoparticles such as those synthesised by Im et al.13 (Fe3O4/MnO) and Kim et al.14 (Gd-
doped iron oxide nanoparticles) have also shown enhanced T1 contrast while retaining the T2 
effects.  
Although inorganic nanoparticle hybrids have shown some promising results, simple 
conjugation of a paramagnetic chelate to the surface of iron oxide nanoparticles is an even 
more attractive method to produce dual-mode contrast agents according to the reports 
published so far.15–18 The theoretical assumption is that these simpler combined agents will 
present an enhanced r1 without the r2 being significantly affected. Actual results however, are 
much more complex. Yang et al 15 and Bae et al 16 showed independently with different T1/T2 
systems, that r2 strongly decreases when iron oxide nanoparticles are conjugated to Gd 
chelates, accompanied by an enhancement in the r1. Choi et al 17 also observed the same 
trend with a possible dependence on the distance between the Gd and the magnetic core. 
Finally, Huang et al 18 showed the opposite trend where both r1 and r2 increased with Gd 
concentration when the T1 and T2 moieties were coupled. In all these cases, r1 increases when 
Gd is incorporated. However, the r2 trends are not consistent between different 
publications/systems. 
These contradicting results demonstrate that further studies are required to understand the 
relationship between the final relaxation rates and the design and structure of the T1/T2 probes. 
Thus, in this research, a systematic series of iron oxide nanoparticles functionalised with Gd 
chelates were prepared to better understand the effect of this interaction on the final relaxivity 
of the system, as well as to search for the ideal (dual) MRI probe design. A rational screening 
of different parameters arising from the combination of these T1 and T2 moieties was 
performed i.e. nature of the organic coating of the magnetic nanoparticles, distance between 
the magnetic and paramagnetic components, magnetic properties, and nature and 
presentation of the paramagnetic component. 
 
MATERIALS AND METHODS: 
General: 
All reagents except DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) 
(CheMatech) and PEG molecules (Quanta Biodesign and Iris Biotech) were purchased from 
Sigma-Aldrich and used as supplied. 6 nm Fe3O4 nanoparticles were prepared according to 
Sun et al.19 by thermal decomposition. Fourier transform infrared (FT-IR) spectra were 
recorded using a Perkin Elmer Spectra 100 FT-IR Spectrometer. UV-Vis spectra were 
recorded using a Perkin Elmer Lambda 25 UV/Vis Spectrometer. A JEOL 2010 transmission 
electron microscope working at 200 keV was used to image the nanoparticles. Hydrodynamic 
size studies were performed either/both on a Malvern Zetasizer Nano ZS instrument or a 
Perkin Elmer Delsa NanoS. T1 and T2 relaxation times were measured with a Minispec mq60 
relaxometer working at 1.47 T and selected samples were measured also in a DRX400 Bruker 
NMR spectroscope at 9.4 T. Imaging was performed in a 3T horizontal bore MR Solutions 
Benchtop MRI system (Guildford, UK) equipped with 48 G/cm actively-shielded gradients. For 
imaging the sample, a 56-mm diameter quadrature birdcage coil was used in transmit/receive 
mode. 
Ligand exchange on 6 nm Fe3O4 nanoparticles with 11-aminoundecanoic acid 
Prior to the ligand exchange, 2 mL (3 mg/mL Fe) of the original nanoparticle solution were 
washed extensively three times with methanol, and twice with each ethanol and acetone (5 
mL each), followed by centrifugation for 5 minutes at 17000 g. Finally the sample was 
resuspended in THF (4 mL) and mixed with water (4 mL) containing 11-aminoundecanoic acid 
(50 mg, 0.24 mmol). This solution was stirred for 48 h and then was directly centrifuged for 5 
minutes at 17000 g, the supernatant discarded and the pellet washed in the same way with a 
1:1 mixture of THF:water (5 mL total). Finally the pellet was resuspended in water (2 mL) and 
stored in the fridge until further use. 
Ligand exchange on 6 nm Fe3O4 nanoparticles with alendronic acid 
Bulk oleic acid-capped nanoparticles (2 mL, 3 mg/mL Fe) were precipitated out of hexane and 
resuspended in THF (2 mL). Sodium alendronate trihydrate (50 mg) was dissolved in water (5 
mL) and the pH adjusted to 9 with 1 M KOH. The THF solution of the nanoparticles was added 
to the ligand solution, and stirred for 2 days at room temperature. Then, the stirrer bar was 
removed and the nanoparticles isolated with a magnet. The supernatant was decanted and 
the black solid suspended in water (2 mL). Acetone (10 mL) was added to wash out any 
remaining ligand and this was repeated a further two times. Finally, the nanoparticles were 
resuspended in water (5 mL) and the pH checked to ensure it was at pH 8 (adjusted 
accordingly with KOH solution). 
Fmoc-PEGx-CO2H coupling 
Bifunctional carboxylic/Fmoc PEG molecules of different molecular weights were used for the 
fuctionalisation of the nanoparticles. In general, Fe3O4 nanoparticles (1 mg, 1.6 x 10-9 mol) 
were mixed in DMSO (2 mL) with PEG (1.6 x 10-6 mol), and EDC (10 mg, excess) was added 
to the solution. The reaction was allowed to take place overnight. Next day the sample was 
centrifuged (17000 g, 5 minutes), the supernatant discarded, and the pellet washed three 
times with water in the same way. Then, to deprotect the amine, the pellet was resuspended 
with ultrasonication in a 80/20 mixture of DMF/piperidine (5 mL) and shaken for 15 mins. After 
centrifugation under the same conditions, this deprotection step was repeated two more times 
and finally the pellet was resuspended in water and stored in the fridge until further use. 
DOTA coupling 
DOTA (194.1 μg, 4.8 x 10-7 mol) was activated in water with EDC (100.8 μg, 5.28 x 10-7 mol) 
and NHS (93.23 μg, 8.1 x 10-7 mol). After 90 minutes the product of this reaction was mixed 
with PEG functionalised nanoparticles (1 mg, 1.6 x 10-9 mol), and stirred overnight. To purify 
the final product, acetone (1 mL) was added and the particles were centrifuged (17000 g, 5 
minutes). The supernatant was kept to calculate the yield of the reaction and the pellet was 
washed two more times in the same way (acetone addition followed by centrifugation). Finally 
the nanoparticles were resuspended in water (2 mL), aliquoted, and stored in the freezer until 
further use. 
The yield of the DOTA coupling was measured by incubating the washings from the coupling 
reaction with a known amount of GdCl3 overnight and subsequently measuring the amount of 
free non-chelated Gd(III) using xylenol orange and UV-Vis spectroscopy (ESI, S3).20 
Gd(III) chelation 
In a model reaction, DOTA-functionalised nanoparticles (1.3 x 10-9 mol) were mixed in acetate 
buffer (2 mL, 0.2 M, pH 6.5) with a solution of GdCl3.6H2O (12.36 μg, 7.86 x 10-8 mol). The 
mixture was shaken overnight. After this time, the solution was destabilised by the addition of 
acetone (1 mL) and centrifuged for 5 minutes at 17000 g. The supernatant was discarded, and 
the pellet was resuspended in water (2 mL) and stored until further use. 
The amount of Gd(III) was calculated from three independent ICP-OES measurements.  
Relaxivity measurements  
Four aqueous dilutions of different nanoparticle concentrations (between 0 and 0.6 mM Fe 
and 0 and 0.02 mM Gd, when present) were prepared of each sample. For measurements in 
the Minispec (1.47 T) 200 L of samples were prepared in relaxometer tubes in water. For 
measurements at 9.4 T, the samples (600 L) were placed in standard NMR tubes along with 
a capillary tube filled with deuterated water to facilitate the locking. Standard CPMG and 
saturation recovery sequences were used for T2 and T1 measurements respectively. All 
experiments were performed at 37oC. The relaxivity constants (both r1 and r2) were calculated 
as the slope of the curve fitting T1-1 or T2-1 values versus the metal of interest concentration in 
mM. 
TEM sample preparation 
The nanoparticles were deposited from their solutions (7 µL) onto holey carbon TEM grids 
with 300 mesh (Agar Scientific, UK) and dried at room temperature before the imaging. 
Magnetic measurements 
The magnetic properties of the hybrid systems were measured in a superconducting quantum 
interference device (SQUID) from Quantum Design. For the sample preparation, 20 µL of the 
solution sample were introduced in a PTFE sample holder also provided by Quantum Design. 
Then, the solvent was evaporated under vacuum until the sample was perfectly dry. 
Afterwards, the sample holder was closed and placed in a brass row. Magnetization curves 
as a function of the magnetic field (hysteresis loops) were measured at room temperature and 
2 K under an applied magnetic field up to 2 T. 
MR imaging 
For the phantom measurements, the samples at different concentrations (between 25 and 100 
µM in Fe/Gd) were dissolved in 200 µL of water in 300 µL tubes. All MR images of the 
phantoms were acquired with an image matrix 256x252, FOV 60x60 mm, 3 slices with a slice 
thickness of 1 mm and 1 mm slice gap. For T2-weighted imaging a fast spin echo (FSE) 
sequence with the following parameters was used: TE = 11 ms, TR = 12000 ms, NA = 32. For 
T1-weighted imaging a fast spin echo based (FSE) sequence with the following parameters 
was used: TE = 11 ms, TR = 720 ms, NA = 32. 
 
RESULTS: 
The most straightforward idea to combine T2 and T1 effects into a single probe is the direct 
coupling of both species currently approved for human diagnostics, namely Gd(III) chelates 
and iron oxide nanoparticles. This strategy, in principle simpler than inorganic 
approaches,12,17,21,22 seems also more interesting as, according to previous reports,15,16,18,23 
unexpected effects arising from this coupling can be observed in the final performance of the 
contrast agents. In this sense, this approach allow us to finely tune several design parameters 
that affect the relaxivity properties of the nanoprobes, independently from each other, and so 
establish a cause-effect relationship on their relaxivity properties and their suitability as T1 
and/or T2 MRI probes. In our search for the ideal MRI contrast agent we decided to 
systematically explore this approach through the evaluation of fully characterised iron oxide 
nanoparticles functionalised with DOTA-Gd(III) molecules. This study was divided into several 
sample subsets to evaluate the effect of different parameters into the final relaxivity 
performance (Scheme 1). First, different molecules were studied as protecting/stabilising 
ligands on the nanoparticles (set 1). Once this first step was optimised, different T1 moieties 
were evaluated (set 2), and finally, the effect of the distance between the T1 and T2 
components was also examined (set 3). 
 Scheme 1. Overview of the different modifications to the T1/T2 systems, with the particular modification 
of each set highlighted by the dashed lines. 
To evaluate the potential interactions between T2 and T1 moieties in a single probe, iron oxide 
magnetic nanoparticles were covalently functionalised with Gd chelates. A thermal 
decomposition protocol was adopted for the preparation of iron oxide nanoparticles as this 
methodology provides highly crystalline products and the reaction conditions can be closely 
controlled to obtain samples with different particle size and narrow size distribution.24 Highly 
monodisperse magnetite (Fe3O4) nanoparticles of 6 nm of particle size were prepared using 
iron acetylacetonate as starting material, as shown by TEM (Figure 1A, S1).19 Both the phase 
formation and high crystallinity of the nanoparticles were evidenced by selected area electron 
diffraction (SAED) and X-ray diffraction (XRD). The presence of secondary phases due to 
impurities was completely discarded as no extra reflexion peaks were identified. (Figure 1). 
 
Figure 1. A, TEM micrograph of as-prepared Fe3O4 nanoparticles (oleic acid capped). B, SAED 
showing Fe3O4 lattice ring patterns. C, XRD diffractogram with indexed peak positions. Scale bar, 100 
nm. 
As-prepared nanoparticles were only soluble in apolar solvents and thus not compatible with 
biological applications. A ligand exchange strategy was chosen to transfer the nanoparticles 
from organic to aqueous solution using more suitable bifunctional water soluble molecules. 
For this purpose, and to investigate the effect of ligands protecting/stabilising the nanoparticles 
on the final relaxivity, the nanoparticle surface was first functionalised with one of the following 
ligands (Scheme 2): 11-aminoundecanoic acid (AUA, a classic bifunctional carboxylic/amine 
small molecule, NP1), O-(2-phophonoethyl)-O´-(2-aminoethyl)pentaethylene glycol (P-PEG6-
NH2, a bifunctional phosphate/amine ligand, NP2), or alendronic acid, (ALA, a bifunctional, 
bisphosphonate/amine molecule, NP3). Phophates/bisphosphonates have not been explored 
as much as carboxylates as iron oxide ligands, but they have also been shown to render water 
soluble nanoparticles with good stability and magnetic properties.6,24–27 To evaluate the 
efficiency of the ligand exchange, the nanoparticles were characterised by infrared 
spectroscopy, (ESI, S2). Functional groups with a strong stretching frequency, such as C-O in 
the carboxylic group (around 1500 cm-1), and the phosphonate resonance (strong P=O stretch 
around 1100 cm-1), can be used to follow the nanoparticle surface functionalization. 
  
Scheme 2. Structures of the series of nanoparticles used in this study 
Modification NP r2 ([Fe]) r1 ([Fe+Gd]) r1 ([Gd]) 
Ligand 
NP1 153.8 ± 25.4 15.0 ± 2.5* ---- 
NP2 178.7 ± 15.2 3.9 ± 1.2* ---- 
NP3 360.0 ± 30.5 29.4 ± 3.2* --- 
Initial 
functionalization 
NP3 360.0 ± 30.5 29.4 ± 3.2* ---- 
NP4 358.6 ± 28.3 17.3 ± 2.4* ---- 
Metal 
NP4 358.6 ± 28.3 17.3 ± 2.4 ---- 
NP5 836.7 ± 51.1 31.6 ± 2.6 451.5 ± 34.4 
NP6 324.5 ± 24.6 14.2 ± 2.1 248.6 ± 20.0^ 
NP7 209.9 ± 19.9 15.8 ± 2.6 192.7 ± 19.8# 
Distance 
NP-Gd 
NP5 836.7 ± 51.1 31.6 ± 2.6 451.5 ± 34.4 
NP8 272.7 ± 16.5 7.0 ± 1.7 191.0 ± 23.6 
NP9 212.7 ± 21.7 6.1 ± 2.1 404.0 ± 29.8 
PEGylation 
NP3 360.0 29.4 ± 3.2* ---- 
NP10 197.6 4.1 ± 1.1* ---- 
NP11 530.8 19.1 ± 2.8* ---- 
 
Table 1. Summary of the relaxivity results obtained in this study. All r values were measured at 1.47T and 37oC in 
water and are expressed in mM-1s-1. *r1 values calculated with respect to Fe concentration. ^r1 value calculated 
with respect to Mn concentration. # r1 value calculated with respect to Zn concentration. 
The transversal relaxivity value, r2, for NP3 (360.0 mM-1 s-1 at 1.47 T and 37o C) was found to 
be higher than most of other iron oxide nanoparticles (IONPs) coated with carboxylate-based 
ligands 28–30 including NP1 (153.8 mM-1s-1). It was found to be also higher than the r2 of 
phosphate protected particles, NP2 (178.7 mM-1s-1). On the basis of the quantum mechanical 
outer sphere theory, the T2 relaxivity is highly dependent, among other factors, on the 
saturation magnetisation of the nanoparticles.31 The preparation method of the nanoparticles, 
together with the nature of the coating ligands (depending on the functional group anchoring 
the ligand to the particle) have been found to greatly affect the saturation magnetisation, 
resulting in differing relaxation rates. Surface effects drastically increase when the particle size 
decreases. In the particular case of magnetite, core-shell structures are generally assumed in 
which the bulk spin arrangement of the core contrasts with the spin canting effects present in 
the atomic surface layers, which are supposed to be the reason of a decreasing saturation 
magnetisation as the particle size is reduced. This phenomena has been shown for both 
carboxylate- and phosphate/phosphonate-coated nanoparticles.32 However, advances in 
chemical surface functionalization strategies have re-opened discussions about the effect of 
coating agents on the magnetic ‘dead’ outer layer in magnetic nanoparticles.33,34 In this sense, 
although previous works reported atomic disorder and spin-glass behaviour at the surface of 
magnetite nanoparticles,32,35 more recent studies show evidence of a highly crystallized 
nanoparticle surface with long range atomic order induced by the effect of the anchoring 
groups of coating ligands.36,37 Therefore, different anchoring functional groups affect differently 
the net saturation magnetisation via spin disorder at the nanoparticle surface.32 Spin canting 
is less significant in phosphate-based ligands than in carboxylate-based ones,32 and thus 
phosphate-coated nanoparticles were expected to present a higher magnetisation and 
therefore higher relaxation rates (Figure 3 and ESI, S3). Additionally, the use of high 
temperature thermal decomposition synthesis technology is known to lead to IONPs with 
superior crystallinity, which is also correlated to higher nanoparticle magnetisation.38,39 These 
two factors, the lack of spin canting, and the high crystallinity of the core, justify the 
exceptionally high relaxation rate of NP3, and its better performance when compared to NP1 
and NP2. 
 
Figure 2. Magnetic characterisation of the NPs. A, Room temperature magnetic curves as a function 
of the applied magnetic field for NPs with different ligands (NP1, NP2, NP3). B, Room temperature 
magnetic curves as a function of the applied magnetic field for NPs with different metals (NP3, NP5, 
NP7). C, Room temperature magnetic curves as a function of the applied magnetic field for NPs with 
different functionalisations (NP3, NP5, NP8, NP9, NP10 and NP11)). Results not corrected for 
diamagnetic component from the sample holder. 
The next step of this study was to optimise the nature of the paramagnetic moiety. Gd(III) is 
the most effective paramagnetic metal for use as a T1 contrast agent due to its seven unpaired 
electrons and suitable magnetic moment.40 The main concern with Gd(III) comes from its 
toxicity. Other paramagnetic ions, like Mn(II) (five unpaired electrons in high spin configuration) 
have also been used as T1 contrast agents to some extent. Zn(II), a diamagnetic ion was used 
as a blank in these studies as no magnetic effects are expected from it. In the clinic, Gd(III) 
has to be used in combination with an appropriate chelator to avoid its interaction with 
biological processes.41 The thermodynamic stability and dissociation constant of the resulting 
complexes are crucial parameters that will determine the level of toxicity at the final 
application. The most widely used of these chelates is DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) due to its biocompatibility and good 
stability,42 and therefore, it was selected as the chelator of choice for this study. The 
conjugation of DOTA to the nanoparticles was carried out stoichiometrically, using standard 
peptidic chemistry to couple one of the carboxylic acids on the chelate to one of the amines 
on the surface of the nanoparticles. EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and 
NHS (N-hydroxysuccinimide) were used as coupling reagents. To determine the stoichiometry 
of reagents required, the density of ligands on the nanoparticles was first determined (ESI, 
S4) by TGA to be 1.02 ligands/nm2. The yield of the DOTA coupling reactions was calculated 
measuring the amount of non-reacted chelate through an indirect colorimetric method (ESI, 
S5).20 DOTA coupling yields were >80%. Finally, Gd(III) (or Mn(II)/Zn(II)) was incorporated into 
the nanoparticles via an overnight incubation with GdCl3 (MnCl2/ZnCl2) salts in pH 6.5 acetate 
buffer. Any unbound Gd(III) was removed by centrifugation. The yield of Gd(III) incorporation 
was calculated (from ICP measurements) to be above 95 % (with respect to DOTA) for all the 
samples. 
The incorporation of a paramagnetic moiety on the nanoparticles brings with it a conceptual 
problem in the calculation of the relaxivity rates. The calculation of the r1/2 of a contrast agent 
is achieved by plotting the inverse of the relaxation time versus the concentration of the 
element responsible for the change in the relaxation. While Gd(III) is known to have a 
negligible effect on the transversal relaxation of protons, iron oxide nanoparticles present a 
significant effect on the longitudinal relaxation and therefore could/should be considered for 
the calculation of r1. In these nanoparticulate systems, the concentration of Fe is around one 
order of magnitude higher than that of Gd, which means that when considered together for the 
calculation of the relaxivity, only a small difference is observed from Gd contribution. This is 
why some authors decide to obviate Fe and calculate r1 only in respect to the concentration 
of Gd.12,22 
Prior to comparing the effects of paramagnetic elements on the global relaxivity, r1/2 of NP3 
were compared to those of NP4. As expected, there were no significant changes on the r2 
before and after the coupling of DOTA (360.0 vs 358.6 mM-1s-1). On the other hand, when 
comparing the longitudinal relaxivity, a significant decrease was observed (29.4 vs 17.3 mM-
1s-1). Unlike T2 effects where no contact is needed between the proton and the magnetic 
component (spin-spin relaxation) to effectively modify the longitudinal relaxation, a T1 
relaxation mechanism implies a direct contact between the water molecules and the contrast 
agent. Thus, any modification in the outer shell of the nanoparticles has the potential to change 
the r1. 
The introduction of paramagnetic species in the probe is assumed to have a bigger impact on 
the r1. When considering only the newly introduced element, the obtained r1 values for NP5, 6 
and 7 followed the expected trend; the most paramagnetic ion, Gd(III) presented the highest 
value, followed by Mn(II) (weaker paramagnetic), and then by Zn(II) (451.5 > 248.6 > 192.7 
mM-1 s-1). DOTA-Gd(III) on its own presents a much lower relaxation rate of around 4 mM-1s-1 
at 1.47 T. This difference in relaxivity (from 31.6 to 4 mM-1s-1) results from the combination of 
a multimeric effect on the nanoparticle and changes in the tumbling rate at this field. When r1 
values were calculated considering the combined amount of Fe + Gd (Mn/Zn), the results were 
not that easy to explain. Gd also produced an increase in the r1 (31.6 vs 17.3 mM-1 s-1). 
Surprisingly, both Mn and Zn brought a non-significant decrease in the relaxivity (14.2 and 
15.8 vs 17.3 mM-1 s-1). Due to the low X/Fe ration, only a significant increase is observed in 
the case of X=Gd when the sum of Fe+X is taken as parameter of normalization, because of 
Gd strong effect (7 unpaired electrons) on T1. In the case of Zn, where no magnetic effects 
are foreseen, the relaxivity value showed no change compared NP4. NP6 (Mn2+) does not 
show any significant difference compared to NP4, the behaviour being very similar to Zn. 
Mn(H2DOTA) is 6 coordinate with a distorted octahedral geometry (through solid state crystal 
structure). In solution however, the uncoordinated carboxylates are expected to ionise (due to 
low pKa values).43 Deprotonation of uncoordinated pendant arms could lead to binding of the 
pendant arm to the metal centre, resulting in a net increase in the metal coordination number. 
Mn2+ ion has a maximum coordination number of 8, and when this deprotonation and 
subsequent binding of the pendant arm occurs in solution, the Mn2+ for these particles would 
reach coordinative saturation and only the outer sphere water exchange will contribute to 
relaxation rates.43 
A similar theme is found when analysing the r2 values for the same series of particles. Similarly 
to r1 (Fe+Gd) values, r2 is anomalously enhanced by the incorporation of Gd(III) (836.7 vs 
358.6 mM-1 s-1), in agreement with the higher saturation magnetisation of the hysteresis loop 
(Figure 2 and ESI, S3). To the best of our knowledge, this r2 value is the highest reported to 
date for magnetite nanoparticles of 6 nm size. To double-check this extraordinary value, the 
r2 of this nanoparticle was also measured at 9.4T. The value obtained, 414.61 ± 35 mM-1s-1, 
is still the highest relaxivity reported to date for this kind of particle at high field (the relaxivity 
decreases strongly at high fields). MR images acquired at 3T of phantoms of this samples at 
different concentrations, further confirmed the outstanding properties of NP5, both in T2-
weighted and T1-weighted mode (ESI, S8). Under the imaging conditions used (see materials 
and methods section), NP5 produced a clear change in the contrast in T2-weighted mode at 
any of the concentrations tested. NP3 also produced a significant change at 100 and 50 µM, 
while the nanoparticle with the classic carboxylate ligand, NP1, did not change the contrast 
even at the highest concentration tested (100 µM). In T1-weighted mode, again only NP5 
produced a clear signal. In this case the strongest signal change was observed, as expected, 
from the commercial agent Dotarem® at a concentration of 100 µM in Gd. 
Mn and Zn incorporation brought a decrease in the r2, statistically significant in the case of Zn. 
As mentioned above, both a decrease and an increase in the r2 caused by the coupling of a 
paramagnetic moiety has been reported before.15,16,18 In our system, only Gd shows an effect 
on r2 which suggests that Mn2+ paramagnetism is not strong enough to produce a change in 
the relaxivity of the final probe. In T1/T2 constructs, the increase in r2 has been attributed to an 
alignment of the electronic spins of the paramagnetic ion by the induced magnetic field 
generated by the superparamagnetic particles.12 
In a different set of experiments, the influence of the distance between the superparamagnetic 
and the paramagnetic units was explored. In order to investigate this potential distance 
dependency, a bifunctional carboxy/amine polyethylene glycol (PEG) spacer was included 
between DOTA and the bisphosphonate molecule (ESI, S7). Two different PEG sizes were 
tested, a short PEG comprising 12 units (600Da, NP8), and a long PEG of 96 units (5000Da, 
NP9). The construction of the probes was achieved in three steps. First, PEG molecules were 
coupled to the nanoparticles in water following standard peptidic chemistry. Then, the amine 
terminal side of the PEGs was deprotected in DMF: piperidine (80:20), and finally DOTA was 
coupled stoichiometrically using peptidic chemistry again. To have a better control over the 
system, these complex probes were fully characterised by TGA to determine the average 
number of PEG molecules per nanoparticles (71 PEG600 and 57 PEG5000 per NP, ESI, Table 
S2). 
Relaxivity results for this set of samples showed a clear dependency of the r2 with the distance. 
When the paramagnetic and superparamagnetic components are close by, the final r2 of the 
particles is greatly enhanced (NP4 358.6 vs NP5 836.7 mM-1 s-1). From there, with increasing 
Mw of the PEG, the r2 of the probes decreases to values below that of the original particles 
(NP8 272.7 and NP9 212.7 mM-1 s-1). This r2 distance dependency has already been observed 
by other authors in inorganic systems,17 and was simply attributed to a decrease of the 
magnetic field generated by the superparamagnetic particles with the distance (1/r3, r being 
the distance from the particle). In our system, the hydrodynamic size also increases with PEG 
size (NP5 31.87nm, NP8 37.70nm and NP9 40.70nm, ESI table S3). This decrease in r2 could 
then be the consequence of a weaker magnetic coupling between the superparamagnetic iron 
oxide nanoparticle and the paramagnetic Gd ion as the PEG molecular weight increases. 
r1 (Fe+Gd) values follow the same trend as those of r2 (NP4 17.3, NP5 31.6, NP8 7.0, NP9 
6.1 mM-1 s-1), with an initial increase when Gd is closest to the nanoparticles, followed by a 
significant decrease as the distance between the two moieties is increased. The presence of 
a PEG spacer may account for part of this decrease as the tumbling rate of the chelates 
coupled to these flexible molecules will be faster than that of the chelates directly attached to 
the more rigid alendronic acid (the longer the PEG, the faster the tumbling rate). Furthermore, 
a magnetic interaction between the superparamagnetic magnetite core and the paramagnetic 
Gd complex at that minimal distance could be responsible for the observed r1 enhancement. 
As the length of the PEG chain becomes longer and the packing of the PEG chains around 
the magnetic core is more favoured, this magnetic interaction would disappear and only the 
Gd ion would contribute primarily to the r1, bringing a significant decrease. This is also 
supported by the magnetic results (ESI, S4). The hysteresis loops for the samples NP4 and 
NP5 (minimum distance between Fe3O4 and Gd) show the highest saturation magnetization, 
so that the possibility of a magnetic interaction between the magnetic core and the Gd complex 
must be considered. On the other hand, the longer the PEG spacer, the lower the saturation 
magnetisation. Therefore, in addition to a longer separation distance, a lower intensity of the 
magnetic field coming from the magnetite core, would justify for samples NP8 and NP9 a 
negligible magnetic coupling with the Gd complex and the corresponding significant decrease 
of r1 compared to NP5. When only the concentration of Gd(III) is considered for the calculation 
of the longitudinal relaxivity, there is an initial strong decrease in r1 from NP5 to NP8 (451.5 
vs 191.0 mM-1 s-1) followed by a recovery of the r1 from NP8 to NP9 (191.0 vs 404.0 mM-1 s-1). 
These values are more difficult to rationalise and require a more detailed study of these 
particles and the intermediate functionalised probes. Comparison of the r2 values of NP3, 
NP10 and NP11 (360.0, 197.6 and 530.8 mM-1 s-1) give initially the same trend as the one 
observed when Gd is present; there is an initial decrease in r2 with the short PEG chain. The 
introduction of a longer PEG, surprisingly increases the relaxivity of the probes. r1 values follow 
a similar trend with a decrease with the short PEG and a partial recovery of the r1 with the 
longer PEG. To try to explain these unexpected changes in MR performance, the conformation 
of the PEG molecules on the surface of the particles was studied. PEG molecules can adopt 
two different conformations on a surface, brush (extended), or mushroom (coiled). The space 
that each PEG molecule occupies on the surface of the nanoparticle (D) can be calculated 
and compared to the Flory radius (Rf) of that PEG. If Rf is bigger than D then the PEGs adopt 
a mushroom conformation.44 Calculation of these parameters (ESI, S6) showed that the most 
probable conformation for both PEGs was brush, so the conformation does not help to explain 
the differences in relaxivity. Although this theory has been shown very helpful in many cases, 
for this particular application a more suitable approach that takes into account the curvature 
of the particles might be needed to explain effects like the one observed in here. In our case 
the coupling of a much heavier PEG molecule is only accompanied by a modest increase in 
hydrodynamic size. This might suggest an intermediate PEG conformation between brush and 
mushroom not contemplated in planar models. 
A detailed study of the M vs. H curves for samples NP3, NP10 and NP11 shows a decrease 
of the saturation magnetisation as the PEG chain is introduced, compared to the situation in 
which only alendronic acid is attached to the particle surface (ESI, S4). However, and in 
agreement with the observed trend in relaxivity, the saturation magnetisation recovers as the 
number of ethylene units in the PEG increases (NP11). According to the outer sphere 
relaxation approach, an increase of r2 from NP10 to NP11 would also be expected from the 
observed partial recovery of the saturation magnetisation. However, although the magnetic 
and relaxivity data are in agreement, we believe that more detailed experiments need to be 
conducted in order to assure that the observed relaxivity values are directly coupled 
exclusively to the magnetic data and no other factors, i.e. the degree of freedom of the PEG 
chains.  
  
Conclusion 
The low sensitivity of MRI requires the use of contrast agents, especially in fields like oncology 
where detection of small features (early detection of tumours) is crucial for patient survival. 
Current contrast agents are far from ideal, with severe limitations both in performance 
(particularly at high fields) and ease of diagnosis. The combination of T1 and T2 imaging 
capabilities into a single probe is one of the ways forward, at least in respect to trustworthy 
diagnosis. This field of dual-modal MRI agents is only in its early development and results so 
far lack uniformity. Systematic studies like this one are required to evaluate the effect of the 
coupling of a paramagnetic moiety to a superparamagnetic one. In this report, several 
parameters involved in the design of these dual probes, such as nature of the ligands, spacing 
between the two active components, and nature of the paramagnetic element, have been 
studied in detail. The importance of exerting close control over some of these parameters has 
been highlighted by this work. The distance between the two components is shown to be key 
to maximise the r1/2 of the probes. A close proximity between the paramagnetic and 
superparamagnetic moieties is needed to maximise the potential of the probes. Also, Gd(III) 
seems to be irreplaceable as the paramagnetic moiety, as weaker paramagnetic ions like 
Mn2+, do not exert a sufficiently strong influence on the final probe. 
Even though other parameters (apart from r1 and r2) have to be taken into consideration to 
evaluate the potential of a probe as dual T1/T2 contrast agent (like the r2/r1 ratio), some of the 
nanoparticles reported in this work are incredibly promising for diagnostic applications. For 
example, NP5 shows the highest r2 reported to date for a 6 nm Fe3O4 based particle, and 
NP11 presents a very high r2 together with the stealth properties coming from PEG 
functionalisation. 
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